셀트리온이 그리는 바이오 생태계의 미래: 오픈 이노베이션의 진화와 확장 > K-wave Trends

The four companies selected for this 4th program boast unrivaled technological capabilities in different fields and are expected to further strengthen Celltrion's R&D portfolio. AINB has a platform that designs protein antibodies using artificial intelligence, and has the ability to dramatically increase the speed of discovery of new drug candidates. Enbiocell presents an innovative platform that delivers GLP-1 derivatives, the core of the next-generation obesity treatment market, in an oral formulation, showing the potential to change the treatment paradigm centered on existing injections. In addition, Imita Science is expected to contribute to lowering the probability of clinical failure through precise disease modeling and drug evaluation technology that mimics actual biological tissue. Lastly, Podo Therapeutics is focusing on providing precision medical solutions optimized for each patient based on patient-derived organoid technology.

Celltrion’s open innovation strategy is differentiated in that it goes beyond simply purchasing technology and provides a detailed ‘customized growth roadmap’ tailored to the company’s growth stage. The selected companies have passed rigorous verification by a panel of external technology evaluators and industry experts, and will explore the possibility of joint research and commercialization by combining them with Celltrion's research infrastructure. Celltrion's position is that it will go beyond simple mentoring and will not spare any support for technological advancement if it is a technology that can be linked to research and development needs. From a startup perspective, this is evaluated as a complementary win-win model that lowers market entry barriers by utilizing the global network and infrastructure of large corporations, while Celltrion expands the scope of its independent R&D.

Looking at the achievements of past leaders, it is clear how fruitful Celltrion's open innovation model is. Enterobiome, the first company, took advantage of Celltrion's support and achieved the feat of becoming the first Korean company to win KLSAP, a global bio cluster contest, and attracting 10 billion won worth of investment. Biome, a second-stage company, has secured momentum for new drug development by attracting equity investment from Celltrion, and third-stage companies are also improving the perfection of their technology through ongoing joint research agreements with Celltrion. These success stories are not simply the result of good luck, but are the result of a chemical combination of Celltrion's know-how in developing new drugs and the agile technology of startups.

Celltrion's actions are becoming more solid with the Global Biotechnology Research Center in Songdo, Incheon, and this can be seen as a stepping stone to the global market beyond the domestic market. Celltrion, which is already expanding the base of the bio ecosystem through collaboration with the public sector such as the Incheon Startup Park development project and the K-Bio Lab Hub project, is planning to expand the open innovation program to global hubs such as the United States, Japan, and China in the future. This reflects Celltrion's strong will to help Korea's biotechnology no longer remain in the domestic market but become a standard in the global market. A virtuous cycle is being completed in which the process of nurturing promising startups itself becomes Celltrion's future competitiveness.